1.06
1.06 (0%)
As of Apr 25, 2025
Pyxis Oncology, Inc. [PYXS]
Source:
Company Overview
Pyxis Oncology is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC) tumors.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (617) 221-9059 |
| Industry | |
| CEO | Lara Sullivan, M.D. |
| Website | pyxisoncology.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $16.1 |
| Operating Profit | $-89.5 |
| Net Income | $-77.3 |
| Net Cash | $9.8 |
Profit Ratios
| Gross Margin | $15.7 |
| Operating Margin | -554.1 |
| Profit as % of Revenues | -20.3% |
| Profit as % of Assets | -46.7% |
| Profit as % of Stockholder Equity | -64% |
Management Effectiveness
| Return on Equity | -64% |
| Return on Assets | -49.2% |
| Turnover Ratio | 9.8% |
| EBITA | $-89.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $157.2 |
| Total Liabilities | $36.4 |
| Operating Cash Flow | $-57.7 |
| Investing Cash Flow | $8.2 |
| Financing Cash Flow | $59.3 |
